CD274 and prostate carcinoma: Some studies provided evidence PD-L1 was more expressed in castration-resistant prostate cancer (32.1% positive tumors) than in primary prostate tumors androgen-sensitive (7.7% of positive tumors) and was particularly pronounced in neuroendocrine prostate cancers [391].